Publication date: Available online 11 January 2018
Source:Radiotherapy and Oncology
Author(s): Evelyn M. Monninkhof, Juliette W.L. van Loon, Marco van Vulpen, Linda G.W. Kerkmeijer, Floris J. Pos, Karin Haustermans, Laura van den Bergh, Sofie Isebaert, Gill M. McColl, Robert Jan Smeenk, Juus Noteboom, Iris Walraven, Petra H.M. Peeters, Uulke A. van der Heide
PurposeTo compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour.Material and methodsFLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm (n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions. The dose-escalated treatment arm (n = 284) received 77 Gy in 35 fractions to the entire prostate, with an integrated boost up to 95 Gy to the multi-parametric MRI-defined (macroscopic) tumour within the prostate. Treatment related toxicity was measured using the CTCAE version 3.0. Grade 2 or worse GU or GI events up to two years were compared between groups by presenting proportions and by Generalized Estimating Equations (GEE) analyses for repeated measures.ResultsNinety percent of the 571 men randomly assigned between September 2009 and January 2015 had high-risk disease (Ash 2000), of whom nearly 66% were prescribed hormonal therapy up to three years. Median follow-up was 55 months at the time of this analysis. Toxicity prevalence rates for both GI and GU increased until the end of treatment and regressed thereafter, with no obvious differences across treatment groups. Late cumulative GI toxicity rates were 11.1% and 10.2% for the standard and dose-escalated group, respectively. These rates were 22.6% and 27.1% for GU toxicity. GEE analyses showed that both GU toxicity and GI toxicity (≥grade 2) up to two years after treatment were similar between arms (OR 1.02 95%CI 0.78–1.33p = 0.81 and (OR 1.19 95%CI 0.82–1.73p = 0.38), respectively.ConclusionsIn intermediate- and high-risk prostate cancer patients, focal dose escalation integrated with standard EBRT did not result in an increase in GU and GI toxicity when compared to the standard treatment up to two years after treatment. This suggests that the described focal dose escalation technique is safe and feasible.
from Imaging via alkiviadis.1961 on Inoreader http://ift.tt/2DG2Xyu
Κυριακή 28 Ιανουαρίου 2018
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vzMRTg via IFTTT
-
-
Vol.83 No.3 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TkQfWM via IFTTT
-
Editorial introductions No abstract available Editorial: COVID-19 in older persons: the role of nutrition No abstract available A year with ...
-
Small size of metastatic lymph nodes with extracapsular spread greatly impacts treatment outcomes in oral squamous cell carcinoma patie...
-
Abstract We generated an alternative reverse genetics (RG) system based on a synthesized swine 45S rRNA promoter to rescue the H3N2 subtype...
-
Abstract In present work, the electronic structure and optical properties of the FeX 2 (X = S, Se, Te) compounds have been evaluated by t...
-
A frame deformation estimation algorithm is investigated for the purpose of real-time control and health monitoring of flexible lightweight ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου